Breaking News

Financial Report: Gilead

April 27, 2012

Product sales up 19%


1Q Revenues: $2.3 billion (+19%)

1Q Earnings: $437.5 million (-32%)

Comments: Revenue growth in the quarter was driven by increased sales of Atripla and Truvada, and the launch of Complera/Eviplera. Atripla sales increased 19% to $887.6 million and Truvada sales were up 13% to $758.3 million. Sales of Complera/Eviplera more than doubled to $52.2 million compared to 4Q11. Sales of Viread increased 14% to $191.7 million. Royalty, contract and other revenues from collaborations were $74.1 million in the quarter, up 19%. Earnings included $193.9 million of acquisition-related compensation expense related to the Pharmasset acquisition.
blog comments powered by Disqus
  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • The Search &  Rescue Mission for Data Integrity

    The Search & Rescue Mission for Data Integrity

    Mike Jovanis, Vice President of Vault QualityDocs, Veeva Systems||October 11, 2016
    Cloud technology is essential for success